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Abstract 
The aim of this paper is to analyse the US Supreme Court’s decision 
in the Bowman v. Monsanto case, examine the arguments of the parties and 
assess their validity under European legislation and compare it with the US 
legal regulation. This paper also discusses particularities of patent and plant 
variety rights systems’ regulations, their historical origins and evolution, as 
well as interrelation between these two systems of biological material 
protection in the field of agriculture.With regard to the analysis of the US 
and European legislation it is concluded that despite some differences in the 
regulation of the patent protection in the field of biological matter, even if 
the Bowman v. Monsanto case had been examined in Europe, the final 
decision of the European court would not differ from the judgment of the US 
Supreme Court. 
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Introduction 
Since the introduction of agriculture it is very common for a farmer 
to save some of the harvested crops as seeds for the replantation in the next 
year’s growing season. Such practice was a long-term tradition that lasted 
through the centuries and ensured the well-being of farmers’ families. 
However, developing technologies and inventions bring various changes to 
well-established habits, also in the field of agriculture. It also modifies the 
approach to what is allowed and what is not. Therefore, while the industry 
and business world adopt these changes normally, it is usually not a simple 
task for the farmers. One of the challenges farmers face nowadays is the 
cultivation of genetically modified plants and animals. Since genetically 
modified organisms did not come into being from the nature as a 
consequence of natural processes, but rather were the result of the scientific 
intervention, therefore the usual methods and rules of dealing with biological 
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material in these cases are not always valid. This raises the question of 
whether the farmers are allowed to deal with genetically modified organisms 
in the same way as with those that are not modified genetically; and if not, 
what are their rights in this field. One of the cases relating to the examination 
of the abovementioned issue is the Bowman v. Monsanto case, already called 
a landmark case for the farmers in the United States. This decision is also 
very important for the US patent law because it was the first case addressed 
to the US Supreme Court where it had to analyse and explain the 
applicability of patent exhaustion principle in the context of self-replicating 
technologies. Accordingly, the aim of this article is to analyse the decision of 
the US Supreme Court in the Bowman v. Monsanto case, as well as the legal 
regulation of the United States and the European Union, and discuss whether 
a European court would make same or similar decision under the same set of 
facts. In this context it should be also noted that in this article the term 
"European" in most cases will be used as a synonym for the EU. 
 
Background of the Bowman v. Monsanto case 
Facts of the case 
On 13th of May, 2013 the Supreme Court of the United States 
decided against the defendant Bowman and confirmed the judgments of the 
United States Court of Appeals for the Federal Circuit and of the District 
Court for the Southern District of Indiana in case No. 11–796. 
Monsanto Company (hereinafter referred to as “Monsanto”) is an 
enterprise that invented and patented seeds of soya beans (called “Roundup 
Ready” soya beans) containing a genetic alteration, which makes them 
resistant to the active ingredient of many herbicides - glyphosate. Two 
patents covering different aspects of Roundup Ready technology were issued 
to Monsanto. Patent No. 5,352,605 “covers a process by which Monsanto 
combined two different sequences of DNA to create a new gene called a 
chimeric gene“6, which can give a plant new traits, for instance resistance to 
weed killers. Patent No. RE39,247E deals with the process described in the 
abovementioned patent that aims to create chimeric genes in different plants 
(including soya beans) and make these plants resistant to herbicides. 
Monsanto or its licensed seed producers retails these specially 
manufactured Roundup Ready soya bean seeds to farmers and licences the 
use of Roundup Ready seed technology. According to the terms and 
conditions of the license agreement (so called 'the Technology Agreement') 
Monsanto permits buyers to use the seed containing Monsanto gene 
technologies for planting a commercial crop to one, and only one, growing 
                                                          
6Caruvana D., Holton-Basaldua C. A. Vernon Hugh Bowman v. Monsanto 
Company.Retrieved 06.04.2014 from<http://www.law.cornell.edu/supct/cert/11-796>. 
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season. Moreover, Monsanto forbids keeping any of the crops harvested 
from the purchased seed for replanting or selling or otherwise supplying or 
transferring such saved seed to anyone for the purpose of planting. The 
growers of the Roundup Ready soya beans are only permitted to sell the crop 
resulted from these seeds to the grain elevators (i.e. these second generation 
seeds can be sold only as a commodity, for instance as human food or animal 
feedstuff), or to consume themselves. It should be noted in this context that 
"Monsanto authorizes [farmers] to sell second-generation seed to local grain 
elevators as a commodity, without requiring [farmers] to place restrictions on 
grain elevators’ subsequent sales of that seed."7 
Vernon Hugh Bowman (hereinafter referred to as “Mr Bowman”) is a 
76-year-old farmer from Indiana in the United States who is engaged in a 
farming business that involves the planting of crops, including soya beans. 
Mr Bowman purchased plaintiff’s patented seeds for his every year first crop 
of the season since 1999. All the time he bought the seeds from Pioneer Hi-
Bred (a company affiliated with Monsanto) and followed the conditions of 
the abovementioned licence agreement; i.e. he planted all the purchased 
seeds and sold his entire harvest to the local grain elevator that would usually 
resell it for human or animal consumption. Since the planting of the soya 
beans for the second crop of the season was more risky, Mr Bowman devised 
a new method how to purchase seed at a lower price. He decided to buy soya 
beans intended for consumption from the local grain elevator and then 
planted them. Mr Bowman supposed that the majority of purchased beans 
will contain the Roundup Ready trait, since the local farmers that used to sell 
their crop to the local grain elevator usually cultivated Roundup Ready soya 
beans. Mr Bowman’s presumption was confirmed when he treated his plants 
with herbicides containing glyphosate and all sprouts without the herbicide 
resistant trait were killed. Then the farmer cropped the rest of the soya beans 
containing that quality and kept some of the seeds for the next season’s 
second crop planting. Time to time Mr Bowman additionally purchased 
some soya bean seeds from the grain elevator in order to supplement his 
second crop planting supply. Accordingly, he harvested eight crops in this 
way. However, eventually Monsanto detected this activity, since it realized 
that Mr Bowman's soya bean harvest is considerably bigger than it could be 
generated from purchases from Pioneer Hi-Bred. Consequently Monsanto 
decided to bring an action against Mr Bowman for patent infringement. 
 
 
 
                                                          
7Petition for a writ certiorari.P. 4.Retrieved 06.04.2014 
from<http://sblog.s3.amazonaws.com/wp-content/uploads/2012/04/11-796-Bowman-v.-
Monsanto-Petition.pdf>. 
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Arguments of the parties and the decision of the US Supreme Court 
The main arguments of the defendant were based on the exhaustion 
doctrine, “which gives the purchaser of a patented article, or any subsequent 
owner, the right to use or resell that article“8. Mr Bowman claimed that he 
was using purchased seeds in the same usual way as other farmers do, so the 
decision in favour of Monsanto, in opinion of the defendant, would create a 
broad exception for self-replicating technologies and thus negate patent 
exhaustion principle9. This would also prevent the farmers from making 
appropriate and effective use of the purchased seeds. In addition the 
defendant argued that soya beans naturally “self-replicate or ‘sprout’ unless 
stored in a controlled manner,” and thus “it was the planted soybean, not 
Bowman”, that made replicas of Monsanto’s patented invention10. 
Meanwhile Monsanto reasoned that the sale of a patented product does not 
grant the purchaser the right to make, use or sell the copies of that product 
and that it is the right of the patentee to license limited rights to licensees and 
purchasers.11 
The Supreme Court upheld the decisions of the lower courts. In its 
unanimous decision the Court stated that exhaustion doctrine is not applied 
for copies of the article, but only for the article itself. The Court emphasized 
that “the doctrine restricts a patentee’s rights only as to the “particular 
article” sold; it leaves untouched the patentee’s ability to prevent a buyer 
from making new copies of the patented item”12. Thus the Supreme Court 
reaffirmed the opinion of the United States Court of Appeals for the Federal 
Circuit that the “fact that a patented technology can replicate itself does not 
give the purchaser the right to use replicated copies of the technology."13 
Regarding Mr Bowman’s argument on the broad and impermissible 
exception of exhaustion doctrine, the Supreme Court pointed out that it was 
Mr Bowman who was asking for an exception from exhaustion principle and 
that such exception would cause low value of the patent of the soya bean 
seeds. The Court also noted that the defendant “was not a passive observer of 
his soybeans’ multiplication; or put another way, the seeds he purchased 
(miraculous though they might be in other respects) did not spontaneously 
                                                          
8Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 1. 
9Reply brief of V. H. Bowman. P. 3.Retrieved 07.04.2014from 
<http://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/briefs-
v2/11-796_pet_reply.authcheckdam.pdf>. 
10Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 9. 
11Brief of respondents Monsanto Company, et al. Retrieved 07.04.2014 
from<http://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/br
iefs-v2/11-796_resp.authcheckdam.pdf>. 
12Bowman v. Monsanto Co., 569 U. S. ___ (2013). P. 6-7. 
13 Opinion of the United States Court of Appeals for the Federal Circuit, decided September 
21, 2011. P.14. 
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create eight successive soybean crops”14. The Court also drew attention to 
the fact that Mr Bowman purchased seeds intended for consumption, 
therefore, in the Court’s view, he stood in a particularly poor position to 
convince that he could not use his soya beans effectively15. 
 
Legal regulation of biological material protection in the field of 
agriculture 
Before going deeper into analysis of arguments of the parties in the 
Bowman v. Monsanto case and their assessment from the European legal 
perspective the author of this article would like to shortly discuss relevant 
legal regulation, its historical origins and evolution. Although "intellectual 
property rights in plants may be of several kinds: patents, plant variety rights, 
trade marks, trade secrets, genetic resource rights"16,in this section the author 
will discuss only the legal regulation for protection of the new breeds of the 
plants in the United States and in Europe which is most relevant to the 
abovementioned Bowman v. Monsanto case. 
When we talk about newly invented items it is generally 
understandable and usual that the inventor who spent his/her time and money 
for creating his/her invention seeks to be recognised and rewarded for the 
investment of the time and financial resources put into the research and 
production of the new item. In the context of agricultural inventions it should 
be noted that a person (be it a natural person or a legal entity) that invents 
any new type of plants and seeks to protect inventor's rights usually uses one 
of two ways: on the one hand the breeder can apply for a patent protection, 
on the other hand his/her rights can be protected using plant variety rights 
system. Although both systems have similar goal, i.e. to protect the rights of 
the breeder/inventor of the plant species and promote innovations, the 
conditions for obtaining such protection and the protection granted differ. 
Breeder's decision to choose one of these rights protection systems also 
depends on the national legislation of the particular country, because 
according to Art. 27 (3) (b) of the Agreement on Trade-Related Aspects of 
Intellectual Property Rights (hereinafter referred to as TRIPs) member 
countries of this Convention shall provide at least one legal remedy for the 
protection of plant varieties, i.e. "either by patents or by an effective sui 
generis system or by any combination thereof"17. 
 
                                                          
14Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 9. 
15Ibid. P. 8. 
16Intellectual property protection for plants.Retrieved 17.04.2014 
from<http://www.cipa.org.uk/pages/info-papers-plants>. 
17 Art.27 (3) (b) of the Agreement on Trade-Related Aspects of Intellectual Property Rights 
(TRIPS). 
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Plant variety rights system 
The main international legal act regulating plant variety rights is the 
Convention for the Protection of New Plant Varieties (also called the "UPOV 
Convention"). The UPOV Convention came into force in 1968 and it has 
been revised in 1972, 1978 and 1991. According to Art. 5 of the latest 
version of the UPOV Convention for the breeder's right to be granted the 
new plant variety shall meet four criteria: it must be new, distinct, uniform 
and stable. Once breeder's right is granted the right holder has an exclusive 
right to authorize production or reproduction (multiplication), conditioning 
for the purpose of propagation, offering for sale, selling or other marketing, 
exporting, importing, stocking for any of the abovementioned purposes18. 
However, it should be noted that the rights of the breeder are not unlimited, 
because the UPOV Convention contains some exceptions from breeder's 
rights (for example, compulsory private and non-commercial use and 
research exceptions and optional farmer's privilege (Art. 15), as well as 
exhaustion principle (Art. 16)). Contracting countries of the UPOV 
Convention implemented the provisions of this Convention in their national 
legislation: the United States adopted its Plant Variety Protection Act 
(PVPA), European countries - national plant variety protection laws.19 
Supplementary to the national breeder's rights protection systems at the EU 
level the Community Plant Variety Rights system was established by the 
Council Regulation (EC) No 2100/94 on Community plant variety rights in 
1994. The aim of this Regulation is to provide the possibility to the breeders 
to protect their rights in all EU member states by submitting only one 
application (i.e. the Community Plant Variety Rights System functions 
similar as the Community Trade Mark System). 
In the context of genetically modified plants it should be also noted 
that under the UPOV Convention, "genetically modified crops and the 
intellectual property rights granted to them are no different than the 
intellectual property rights granted for traditionally bred varieties".20 This 
means that the exclusions established in the Convention (such as private and 
non-commercial use or research exceptions or farmer's privilege) can be also 
applied in case of genetically modified plants. 
 
 
                                                          
18 Art.14 of the Convention for the Protection of New Plant Varieties. 
19 For more information about plants varieties protection legislation in particular countries 
see <http://www.upov.int/upovlex/en/>. 
20Wikipedia on International Union of the Protection of New Varieties of Plants.Retrieved 
17.04.2014 
from<http://en.m.wikipedia.org/wiki/International_Union_for_the_Protection_of_New_Vari
eties_of_Plants>. 
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Patent protection on plants 
Firstly, it should be noted that having regard to the option established 
in Art. 27 (3) of TRIPs many Contracting countries to the TRIPs excluded 
plants and inventions directed to plants and plant products from patentability. 
However, it was not the case in the United States which courts in their 
jurisprudence recognize that any biological material that is a result of human 
intervention is considered as a composition of matter and therefore is a 
patentable subject matter according to Art.101 of the US Patent Act 
(Diamond v Chakrabarty(1980) 447 US 303). Moreover, “the United States 
has extended patent protection to plants produced by either sexual or asexual 
reproduction and to plant parts including seeds and tissue cultures (Ex parte 
Hibberd(1985) 227 USPQ 433)”21. It should be also noted that the US Patent 
Act contains separate provisions for specific plant patents, stating that: 
"whoever invents or discovers and asexually reproduces any distinct and 
new variety of plant, including cultivated sports, mutants, hybrids, and newly 
found seedlings, other than a tuber propagated plant or a plant found in an 
uncultivated state, may obtain a patent therefor, subject to the conditions 
and requirements of this title" (Art. 161 of the US Patent Act).  
Meanwhile the lawmakers of the European countries followed 
regulation provided in the Strasbourg Patent Convention, later in the 
European Patent Convention, and established provisions stating that patents 
shall not be granted in respect of plant varieties or essentially biological 
processes for the production of plants (Art. 53 (b) of the European Patent 
Convention). In 1998 the new legal instrument at the European Community 
level was proposed - the Directive 98/44/EC on the patenting of living 
material, which enabled patent protection for some inventions related to the 
plants (namely it recognizes that the inventions which concern plants are 
patentable provided that the application of the invention is not technically 
confined to a particular plant variety). 
As it was mentioned above conditions for obtaining patent protection 
differ from the conditions established for plant variety rights system. For the 
patent to be granted the invention's "patent application must show: 1) 
novelty, 2) non-obviousness, or an inventive step, 3) usefulness (United 
States) or industrial applicability (Europe, Australia), 4) enablement, 5) 
claim clarity, 6) written description, 7) best mode (United States only)".22 As 
for the specific plant patent the requirements for patentability are the same as 
for usual patent (so called ‘utility patents), however, “the implementation of 
these requirements is less stringent”23 for the plant patents. Moreover, 
                                                          
21 Can IP rights protect plants? Retrieved 17.04.2014 
from<http://www.patentlens.net/daisy/patentlens/1234.html>. 
22Ibid. 
23Ibid. 
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according to the US law the same plant can be patented by both plant patent 
and utility patent provided that the application of the invention fulfils 
requirements for both kinds of patents. 
 
Interrelation between patent and plant variety rights systems’ 
regulation 
Although both discussed inventor's right protection systems are 
independent, over time they made an impact to each other's provisions. Since 
the very adoption of the UPOV Convention it was thought that UPOV 
Convention (namely Art. 2 (1)) contains prohibition of dual protection of 
breeder’s rights. According to Llewelyn, “this view was based on a 
misreading of the provision which was not intended to prevent member 
states from providing both patents and plant variety rights over plant 
varieties.”24 Having regard to the abovementioned provision the draftsmen of 
the Convention on the Unification of Certain Points of Substantive Law on 
Patents for Invention (also called ‘the Strasbourg Patent Convention’) 
included plants related inventions’ exception from patentability (Art. 2 (b)). 
Later similar provision was transposed into the European Patent Convention 
(Art. 53 (b)).  
In 1991 the dual protection prohibition was removed from the text of 
the UPOV Convention, “because it was recognised that there were 
misconceptions as to the interpretation and application of the prohibition”25. 
However, the exclusion of plant varieties protection from patentability 
remained in the European patent legislation. Only in 1998 when the 
Directive 98/44/EC was proposed the strict prohibition on the patenting of 
biological material has been toned down. It should be also noted that (as we 
will see later in the section 3 of the article) the provisions of the UPOV 
Convention have influenced the establishment of exclusions and limitations 
from patent protection imposed for the biological material inventions (at 
least in the European Union and some other European countries). 
 
Analysis of parties’ arguments from the European perspective  
Patentability of the plants 
Although Mr Bowman did not dispute the patentability of Monsanto 
inventions before US courts, it can be assumed that he would try to raise this 
question if the case was heard by the European court. In this respect he could 
argue that according to Art. 53 (b) of the European Patent Convention 
Monsanto's invention is not patentable. Nevertheless, such argument would 
                                                          
24Llewelyn, M. From ‘outmoded impediment’ to global player: the evolution of plant variety 
rights. In Intellectual Property in the New Millennium.Essays in Honour of William R. 
Cornish.Cambridge University Press. Cambridge. 2004. P. 150. 
25Ibid. 
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be rejected by the European court with reference to the following reasons.  
Firstly, as it was mentioned above the institutions of the European 
Union adopted directive which provides the possibility to patent some of the 
plants related inventions. Member states of the EU have accordingly changed 
and/or supplemented their national patent legislation. This means that the 
invention of Monsanto still could be patentable in the member states of the 
EU, because the application of the invention is not confined to a single plant 
variety.  
Secondly, as about the European countries that are not members of 
the European Union, but are Contracting parties to the European Patent 
Convention (such as for example, Norway, Iceland or Switzerland), the 
decision of their courts on the issue of the patentability of Monsanto’s 
invention would be still the same as of the courts of the EU members states. 
This conclusion is based on the analysis of the national laws of the 
abovementioned countries and the case law of the European Patent Office. 
For example, Sec. 1 of the Norwegian Patents Act contains the provision 
stating that: “a patent cannot be granted in respect of plant or animal 
varieties. Inventions that concern plants or animals may, however, be 
patentable if usage of the patent is not technically limited to one particular 
plant or animal variety”26. Similar norms are incorporated into Art.1 of the 
Patent Act of Iceland (“a patent shall not be granted for plant or animal 
varieties. It is however possible to grant patents for inventions pertaining to 
plants and animals if the implementation of the patent is not confined for 
technical reasons to a particular plant or animal variety”27) and Art. 2 (2) 
(b) of the Swiss Federal Act on Patents for Inventions (“also excluded from 
patentability are: <...> b. plant varieties and animal varieties or essentially 
biological processes for the production of plants or animals; however, 
subject to the reservation of paragraph 1, microbiological or other technical 
processes and the products obtained thereby as well as inventions that 
concern plants or animals are patentable provided that their application is 
not technically confined to a single plant or animal variety”28).  
On the other hand the patentability of some plants related inventions 
was examined by the European Patent Office. For example the Enlarged 
Board of Appeal in its decision in the case No. G 0001/98 indicated that Art. 
53 (b) of the European Patent Convention should be interpreted as not 
                                                          
26The Norwegian Patents Act.Retrieved 06.04.2014 
from<http://www.patentstyret.no/en/For-Experts/Patents-Expert/Legal-texts/The-
Norwegian-Patents-Act/>. 
27The Patent Act of Iceland.Retrieved06.04.2014 
from<http://www.wipo.int/wipolex/en/text.jsp?file_id=190418>. 
28The Swiss Federal Act on Patents for Inventions.Retrieved 06.04.2014 
from<http://www.admin.ch/opc/de/classified-compilation/19540108/index.html>. 
European Scientific Journal December  2014 edition vol.10, No.34 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
32 
excluding patent claims that embrace plant varieties, provided that specific 
plant varieties are not individually claimed in respective claims29. Analogous 
arguments by the European Patent Office were also presented in subsequent 
cases (for example, in the case No. T 0149/98 (Resistance 
development/BAYER) of 15.1.200330 and the case No. T 0179/01 (Herbicide 
resistant plants/MONSANTO) of 6.4.200531). 
 
Exhaustion doctrine 
As already mentioned above, the main arguments of the defendant in 
the Bowman v. Monsanto case were based on the patent exhaustion doctrine. 
Mr Bowman argued that patent exhaustion has been the law in the United 
States for more than 150 years. He also referred to the Supreme Court’s 
decision in United States v. Univis Lens Co., 316 U.S. 241 (1942) case and 
its predecessor cases where, according to Mr Bowman, the Court "articulated 
the clear rule that a sale authorized by the patent owner exhausts patent 
rights in the article sold."32 
The exhaustion doctrine (also called “first sale doctrine”) is a concept 
in intellectual property law. The application of this doctrine implies that an 
authorized, unconditional sale of the individual article protected by 
intellectual property law terminates all right holder’s rights to control the 
transfer of that particular item. Exhaustion of rights rule causes not only 
legal, but also economic consequences; therefore it is particularly important 
in the European Union that seeks to ensure the free movement of goods 
between the member states under normal conditions of competition. 
First sale theory is relevant in various fields of intellectual property 
law, although in each of them it has its own particularities. Thus the main 
goal of the doctrine of exhaustion in patent law is to ensure an appropriate 
balance between the interest of the patent owner „in obtaining a reasonable 
reward for its invention on the one hand, and the interests of the general 
                                                          
29Decision of the Enlarged Board of Appeal of the European Patent Office, No.G 0001/98 
(Transgenic plant/NOVARTIS II) of 20.12.1999.Retrieved 06.04.2014 
from<http://www.epo.org/law-practice/case-law-appeals/recent/g980001ep1.html#q=>. 
30Decision of the Board of Appeal of the European Patent Office, No. T 0149/98 (Resistance 
development/BAYER) of 15.1.2003. Retrieved 06.04.2014 from<http://www.epo.org/law-
practice/case-law-appeals/recent/t980149eu1.html>. 
31Decision of the Board of Appeal of the European Patent Office, No. T 0179/01 (Herbicide 
resistant plants/MONSANTO) of 6.4.2005. Retrieved 06.04.2014 
from<http://www.epo.org/law-practice/case-law-appeals/recent/t010179eu1.html>. 
32Petition for a writ certiorari.P. 10.Retrieved 06.04.2014 
from<http://sblog.s3.amazonaws.com/wp-content/uploads/2012/04/11-796-Bowman-v.-
Monsanto-Petition.pdf>. 
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public in the free movement of goods and legal certainty on the other“33. It is 
argued that the term ‘exhaustion’ itself is derived from old German case law: 
in Guajakol-Karbonat case in 1902 the Reichsgericht pointed out: "the effect 
of a patent (for a process) is that no-one, except the proprietor (or the persons 
whom he has authorized) may manufacture a product by the said process and 
put it on the domestic market. By this act, however, the effect of the 
protection conferred by the patent is exhausted. The proprietor who has 
manufactured the product and has put it on the market under this protection 
which excludes competition from other parties, has enjoyed advantages 
which the patent confers upon him and has thus exhausted his right."34 
So the patent exhaustion doctrine means that a person who legally 
purchased patented product may use it freely – he may use it for his own 
needs, he may resell it to others, etc. However, it should be noted that „the 
exhaustion of the right does not apply to the patented object as an abstract 
category, family or group, but concerns only the specific object, individually 
and concretely sold“35. In this respect Mr Bowman could also argue that it 
was not the product itself, but the method that was patented by Monsanto. 
Furthermore, Mr Bowman did not use this patented method for the 
production of soya bean seeds. He rather used the purchased seeds “in a 
normal way farmers do”36 and as a result of this “normal use” he got new 
seeds. The contra arguments for this contention could be found in the legal 
acts and the case law of the European countries. Firstly, the provisions of 
national legislation of the EU member states stipulate that where the object 
of the invention is a method, patent protection shall also be granted with 
respect to a product made by such method37. This means that not only the 
process of creating herbicides resistant chimeric genes in soya beans is 
protected under patent law, but also the plant of genetically modified soya 
bean itself. Secondly, “according to the case law of the German Federal 
Supreme Court, rights resulting from method patents cannot be exhausted“38. 
                                                          
33Von Meibom W., Meyer M. Licensing and patent exhaustion: a comparison of German 
and US case law. Retrieved 09.04.2014 from<http://www.iam-
magazine.com/issues/article.ashx?g=639fb4a3-2012-4d8b-af20-2f4260497129>. 
34Stothers, C. Parallel Trade in Europe. Intellectual Property, Competition and Regulatory 
Law.Hart Publishing. Portland. 2007. P. 41. 
35Germinario C. A Comperative Look at Bowman vs. Monsanto in the European Context. 
World Intellectual Property Report, 19 June 2013. Retrieved 07.04.2014 
from<http://www.sib.it/images/stories/allegati/articoli/bowman_monsanto_eu_context.pdf>. 
36Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 2. 
37Art. 5 (4) of the Lithuanian Patent Law; Sec. 9 (3) of the German Patent Act; Art.L613-3 
(c) of the French Intellectual Property Code. 
38Von Meibom W., Meyer M. Licensing and patent exhaustion: a comparison of German 
and US case law. Retrieved 09.11.2013 from<http://www.iam-
magazine.com/issues/article.ashx?g=639fb4a3-2012-4d8b-af20-2f4260497129>. 
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In this respect it could be concluded that a European court would reject Mr 
Bowman’s argument based on exhaustion doctrine. 
 
A need for special regulation of biological material 
Another argument of Mr Bowman was based on the particularity of 
the object-in-question (as a biological self-replicating material) itself. In its 
decision the US Supreme Court made references and analysed two different 
legal acts that deal with the legal protection of newly invented seeds or 
plants: the US Plant Variety Protection Act39 and the Patent Act40. The Plant 
Variety Protection Act establishes a procedure for obtaining a Plant variety 
protection certificate enabling its holder, “during the term of the plant variety 
protection, to exclude others from selling the variety, or offering it for sale, 
or reproducing it, or importing it, or exporting it, or using it in producing 
(as distinguished from developing) a hybrid or different variety therefrom”41. 
Meanwhile the Patent Act is a general legal act for the protection of 
inventions regardless of the subject intended to be patented (be it living 
matter or not), however, also having some specific provisions for plant 
patents. Seeing that the Roundup Ready soya bean seeds were covered by the 
patent, the defendant tried to convince the Court that the Patent Act lacks any 
specific treatment for seeds and therefore the “broad exhaustion doctrine, 
unlimited in the types of uses permitted following an authorized sale”42, 
should be applied. 
If the Bowman v. Monsanto case was heard before European court 
defendant’s argument about the need of specific regulation for biological 
material could be contested by the fact that the legal acts of the member 
states of the European Union contain provisions establishing special 
regulation for patented biological material. For example, Art.L613-2-3 of the 
French Intellectual Property Code43, Sec. 9 (a) of the German Patent Act44 
and Art. 39 of the Lithuanian Patent Law45 provide that where a patent 
concerns biological material possessing specific characteristics as a result of 
an invention, the protection conferred by the patent shall extend to any 
biological material derived from said biological matter through 
                                                          
39Plant Variety Protection Act, 7 U. S. C. §§ 2321 et seq. 
40U.S. Patents Act, 35 U. S. C. §§1 et seq. 
41Sec. 83 (a) (1) of the Plant Variety Protection Act. 
42Brief for petitioner.P. 54.Retrieved 07.04.2014 
from<http://www.americanbar.org/content/dam/aba/publications/supreme_court_preview/br
iefs/11-796_pet.authcheckdam.pdf>. 
43French Intellectual Property Code.Retrieved 07.04.2014 
from<http://www.legifrance.gouv.fr/affichCode.do?cidTexte=LEGITEXT000006069414>. 
44German Patent Act.Retrieved 07.04.2014 from<http://www.gesetze-im-internet.de/patg/>. 
45Lithuanian Patent Law.Retrieved 07.04.2014 
from<http://www3.lrs.lt/pls/inter3/dokpaieska.showdoc_l?p_id=416694>. 
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multiplication or propagation in an identical or diverging form and 
possessing those corresponding characteristics. It should be also noted that 
similar provisions are incorporated into Norwegian46, Icelandic47 and 
Swiss48 patent legal acts. This special regulation means that European 
countries have explicit rule stating that the patent covers not only the 
patented plant, but also the seeds or sprouts gathered from that plant by way 
of propagation or multiplication. Moreover, the national laws of the EU 
member states49 implementing the EU Directive 98/44/EC on the legal 
protection of biotechnological inventions provide that the protection 
conferred by the patent „shall not extend to biological material obtained from 
the propagation or multiplication of biological material placed on the market 
in the territory of a Member State by the holder of the patent or with his 
consent, where the multiplication or propagation necessarily results from the 
application for which the biological material was marketed, provided that the 
material obtained is not subsequently used for other propagation or 
multiplication“50. This clause, according to Germinario, exactly corresponds 
the terms of the license agreement imposed by Monsanto to the purchasers of 
Roundup Ready soya bean seeds51. This means that there is no need for the 
abovementioned license agreements in Europe, since the rights of the patent 
owner in this case would be protected under statutory law. Supporting 
position of the US Supreme Court Germinario also points out that „the 
prohibition against reproducing the object of the patent is completely 
independent from the fact that such an object is endowed with autonomous 
reproductive capacity, since this capability, to be expressed, still needs 
human intervention“52.  
It is obvious from the judgment of the US Supreme Court that it aims 
to protect the inventor of self-replicating invention, where the matter 
otherwise, the patent of this kind of invention would provide inadequate 
benefit53. It can be assumed that the draftsmen of the EU Directive 98/44/EC 
had the same opinion seeing that in the recital 46 of the abovementioned 
Directive they recognize the right for the patent owner to „prohibit the use of 
                                                          
46Sec. 3 (a) of the Norwegian Patents Act. 
47 Art.3 (a) of the Patents Act of Iceland. 
48 Art.8 (a) of the Swiss Federal Act on Patents for Inventions. 
49Art. L613-2-4 of the French Intellectual Property Code; Sec. 9 (b) of the German Patent 
Act; Art.39 of the Lithuanian Patent Law. 
50Art.10 of the Directive 98/44/EC of the European Parliament and of the Council of 6 July 
1998 on the legal protection of biotechnological inventions. OJ L 213, 30.7.1998, p. 13–21. 
51Germinario C. A Comperative Look at Bowman vs. Monsanto in the European Context. 
World Intellectual Property Report, 19 June 2013. Retrieved 07.04.2014 
from<http://www.sib.it/images/stories/allegati/articoli/bowman_monsanto_eu_context.pdf>. 
52Ibid. 
53Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 6. 
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patented self-reproducing material in situations analogous to those where it 
would be permitted to prohibit the use of patented, non-self-reproducing 
products, that is to say the production of the patented product itself“54. The 
need for such right is based on the patent function „to reward the inventor for 
his creative efforts by granting an exclusive but time-bound right, and 
thereby encourage inventive activities“55. 
 
Farmer’s privilege 
The rights of the right holder in the field of intellectual property law 
are not unlimited, for example, the use of a copyrighted work will not be 
considered as an infringement if this work was used for purposes of private 
study, scientific research or teaching, criticism or review, reporting, for the 
benefit of people with a disability, etc.56; meanwhile the purchaser of the 
software has the right to make a back-up copy57. There are also certain 
limitations and exceptions to the protection of plants related inventions, 
however, these exceptions vary depending on different legal acts. For 
instance, the US Plant Variety Protection Act contains: Crop exemption (also 
called „Farmer‘s privilege“) allowing the farmer to save the protected seeds 
and to use such saved seeds in the production of a crop for the use on his 
farm, or for sale as provided in the PVPA58; also a Research exemption 
allowing the use and reproduction of a protected variety for plant breeding or 
other bona fide research59; etc. 
It should be noted that although the farmer’s privilege is included into 
the US Plant Variety Protection Act, it is not a part of the US Patent Act. 
Therefore the arguments of the defendant that were based on this exemption 
were rejected by the US Supreme Court, seeing that the rights of Monsanto 
were protected under the US Patent Act and not under the PVPA. Meanwhile 
in Europe farmer’s privilege is incorporated into Art. 11 (1) of the Directive 
98/44/EC stating that: 
„By way of derogation from Articles 8 and 9, the sale or other form 
of commercialisation of plant propagating material to a farmer by the holder 
of the patent or with his consent for agricultural use implies authorisation 
for the farmer to use the product of his harvest for propagation or 
                                                          
54Directive 98/44/EC of the European Parliament and of the Council of 6 July 1998 on the 
legal protection of biotechnological inventions. OJ L 213, 30.7.1998, P. 13–21. 
55Ibid. 
56Art.5 of the Directive 2001/29/EC of the European Parliament and of the Council of 22 
May 2001 on the harmonisation of certain aspects of copyright and related rights in the 
information society. OJ L 167, 22/06/2001, P. 0010 – 0019. 
57Art.5 of the Directive 2009/24/EC of the European Parliament and of the Council of 23 
April 2009 on the legal protection of computer programs. OJ L 111, 23/04/2009, P. 16-22. 
58Art.113 of the Plant Variety Protection Act, 7 U. S. C. §§ 2321 et seq. 
59Art.114 of the Plant Variety Protection Act, 7 U. S. C. §§ 2321 et seq. 
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multiplication by him on his own farm, the extent and conditions of this 
derogation corresponding to those under Article 14 of Regulation (EC) No 
2100/94“60. 
and Art. 14 of the EU Regulation No. 2100/1994 on Community 
plant variety rights61 providing that: 
„Notwithstanding Article 13 (2), and for the purposes of 
safeguarding agricultural production, farmers are authorized to use for 
propagating purposes in the field, on their own holding the product of the 
harvest which they have obtained by planting, on their own holding, 
propagating material of a variety other than a hybrid or synthetic variety, 
which is covered by a Community plant variety right“. 
The incorporation of the farmer’s privilege into the EU Directive 
98/44/EC and later into the national patent legislation of the EU member 
states is another example of interrelation between patent and plant variety 
rights systems’ regulation. Such incorporation was determined by the 
prevailing opinion expressed in the discussions before the adoption of this 
Directive. It was assumed that the patent protection could have negative 
effect on traditional farming practices. “In particular, it was feared that 
patent protection would mean that farmers would not be able to use the seeds 
that they harvested from their crops to resow crops, nor would they be able 
to breed patented animals”62. Following the EU legislation some European 
non-EU countries also included farmer’s privilege into their national legal 
acts63. 
It would seem that the provisions of the EU legislation cited above 
lead to the conclusion that the decision of a European court in the Bowman 
v. Monsanto case would be different than that which was made by the US 
Supreme Court. However, such a conclusion would be rash and superficial, 
since the exception from the patent protection in favour of the farmers in the 
EU is quite narrow and is a subject to certain conditions. 
Firstly, there is a limitation related to the species of the plants 
cultivated by the farmers. It means that the farmer’s privilege can be applied 
only if the farmer grows the plants expressly indicated in the list provided in 
                                                          
60The equivalent of this provision can be found in national legal acts of EU member states, 
for example, Art. L613-5-1 of the French Intellectual Property Code; Sec. 9 (c) (1) of the 
German Patent Law; Art.35 (5) of the Lithuanian Patent Law. 
61Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant variety rights. 
OJ L 227, 1.9.1994, p. 1-47. 
62Barbosa D. B., Grau-Kuntz K. Exclusions from Patentable Subject Matter and Exceptions 
and Limitations to the Rights. Annex III to Exclusions from Patentability and Exceptions 
and Limitations to Patentees’ Rights. WIPO Standing Committee on the Law of Patents.P. 
64. 
63See Sec. 3 (b) of the Norwegian Patents Act, Art.3 (b) of the Patents Act of Iceland and 
Art.35 (a) of the Swiss Federal Act on Patents for Invention. 
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the EU Regulation No. 2100/1994 (certain types of fodder plants, cereals, 
potatoes, oil and fibre plants). It should be noted that it is a numerusclausus 
list, therefore neither national authorities of the EU member states, nor the 
courts may extend this list by adding any other types of plant varieties such 
as, for example, soya beans. But what was the rationale of this exhaustive list 
and why other types of the plants are not included in it? It can be assumed 
that the legislator intended to protect only those farmers who grow most 
popular types of plants in Europe. Since, for example, soya beans are 
cultivated among European farmers quite rarely (Italy being the biggest 
producer of soya beans in the EU ranks only 15th worldwide64), they are not 
included in the abovementioned list. 
Secondly, the farmers who want to apply the farmer’s privilege are 
obliged „to pay an equitable remuneration to the holder, which shall be 
sensibly lower than the amount charged for the licensed production of 
propagating material of the same variety in the same area“65. The exception 
of this obligation to pay remuneration is provided only to small farmers, 
growing plants on limited area of land. Since Mr Bowman grows plants on 
the area of about 300 acres, according to Germinario, he could not be 
qualified as a small farmer within the meaning of the EU legislation66.  
As for the legislation of the European non-EU countries it should be 
noted that Swiss patent laws does not provide any forms of payments for 
biological material that is reproduced on farm, because the parliament of 
Switzerland by adopting the revised patent act has expressly “rejected the 
introduction of any forms of payment by farmers to holders of patents <...> 
for farm-saved seeds”67.  
 
Economic considerations regarding biological material protection in the 
field of agriculture 
In the Bowman v. Monsanto case the Supreme Court of the United 
States held that by planting and harvesting Monsanto's patented soya bean 
                                                          
64Baseline information on agricultural practices in the EU Soybean (Glycine max (L.)Merr.). 
May 2012. Retrieved 07.04.2014 
from<http://www.europabio.org/sites/default/files/report/120526_report_eu_farming_practic
es_soybean.pdf>. 
65Art. 14 of the Council Regulation (EC) No 2100/94 of 27 July 1994 on Community plant 
variety rights. OJ L 227, 1.9.1994, p. 1-47. 
66Germinario C. A Comperative Look at Bowman vs. Monsanto in the European Context. 
World Intellectual Property Report, 19 June 2013. Retrieved 07.14.2014 from 
<http://www.sib.it/images/stories/allegati/articoli/bowman_monsanto_eu_context.pdf>. 
67Submission on the Implementation of Farmers’ Rights in Switzerland by the Berne 
Declaration (Switzerland).Retrieved 25.04.2014 
from<http://www.evb.ch/cm_data/submission_on_the_implementation_of_farmers_rights.p
df>. 
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seeds Mr Bowman "made additional copies of Monsanto's patented 
invention, and his conduct thus falls outside the protection of patent 
exhaustion."68 As it was already mentioned above, the Court also pointed out 
that if plain making69 of copies was an admissible and rightful use, "a patent 
would plummet in value after the first sale of the first item containing the 
invention."70 Although the US Supreme Court did not make a detailed 
economic analysis it would be useful to look into this dispute from economic 
perspective and examine whether the decision of the Court and current 
European and US legal regulation concerning plants patent protection in 
general can be also justified from a functional point of view. 
The aim of the patent system is to foster innovations "by awarding 
inventors a temporary period of market exclusivity"71, because in the 
absence of such "award" some inventions requiring costly investments would 
not be made72. However, it should be admitted that not all newly invented 
products or processes are patented, because their creators rather try to protect 
their inventions using other intellectual rights protection systems, such as, for 
example, trade secrets, then apply for patent protection. Sometimes it is 
because the invention is excluded from patentability under the laws of 
particular country, but sometimes - because the inventors do not think that 
"the cost of obtaining a patent is justified by the potential returns on the 
patent monopoly"73. The reasons for choosing particular inventions' 
protection system when considering between patents and other intellectual 
property rights protection can be illustrated using inventions' categorization 
developed by Professor Strandburg who classifies them into "self-disclosing" 
and "non-self-disclosing" inventions.74 Self-disclosing inventions, according 
to Professor Strandburg, can be easily copied from their commercial 
embodiments, and in being so they are fully opposites of non-self-disclosing 
inventions. In case of the latter group of inventions the creator will usually 
choose between patents and trade secret protection. He or she will then 
                                                          
68Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 2. 
69It should be noted that some US scholars argue that the term “make” should be interpreted 
narrowly as involving “ an active agent operating to transform a material from one state to 
another state, by which an artificial product results – in other words, to manufacture”. For 
more see. Stern, R. H. Bowman v Monsanto: Exhaustion versus Making. European 
Intellectual Property Review, Vol. 36. Issue 4. P. 258-259. 
70Bowman v. Monsanto Co., 569 U. S. ___ (2013).P. 8. 
71Budish, E., Roin, B.N., Williams, H.Do fixed patent terms distort innovation? Evidence 
from cancer clinical trials.P. 1.Retrieved 05.04.2014 
from<http://economics.mit.edu/files/8651>. 
72Sheff, J. N. Self-Replicating Technologies. Stan. Tech. L. Rev. 229(2013).P. 241. 
73Ibid. 
74Strandburg, K. J. What Does the Public Get? Experimental Use and the Patent Bargain.P. 
3.Retrieved 05.04.2014 from<http://works.bepress.com/katherine_strandburg/4>. 
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calculate the costs of each option (likely the costs for patent application and 
potential costs for litigation in case of patent infringement in comparison to 
the costs for keeping inventions related information in secret) and the 
potential earnings assessed while taking into account the patent protection 
period and the "expected length of time the secret can be maintained"75. 
Given the fact that self-disclosing inventions cannot be kept in secret due to 
their very nature, the creator of such invention has no other option as to 
apply for the patent protection in order to be able to regain the resources 
invested into the creation of the invention.  
Self-replicating technologies (such as plants), according to Professor 
Sheff, are the inventions featuring a characteristic of an extreme form of self-
disclosing76. Thus the application of the exhaustion principle for the second 
and subsequent generation of the seeds could lead to some changes in 
inventors' activity. Firstly, the creator of the patented plants could decide to 
sell the first generation seeds at a high price in order to have possibility to 
retain his/her invested financial resources. However, in this case there is a 
risk that the patent owner will not find a buyer who would accept this price 
knowing that at some later time he/she can also "face the same threat of 
follow-on competition"77. Secondly, the inventor may lose his/her 
willingness to invest and create new self-replicating technologies in general. 
Finally, instead of selling self-replicating items the inventor may decide only 
to sell products manufactured from these inventions and intended for human 
or animal consumption (for example, soya milk, soya flour, soya bean animal 
feed, etc.). All these potential changes of investors’ activity might be 
justifiable from the business point of view. Nevertheless, it might be harmful 
for the general public and the state, because high prices of first generation 
seeds could cause an increase in food prices, while the lack of willingness to 
invest into the creation of new self-replicating technologies could impede 
innovation. Lastly, the decision of the inventors to sell only the end products 
could restrict the public's freedom of choice, because the inventor would be 
then interested in selling only those products which could not disclose their 
technologies78. Thus it can be concluded that the application of exhaustion 
principle to some kinds of self-replicating technologies could be harmful not 
only to the inventors of these technologies, but also to the society.  
However, the establishment and application of certain limitations and 
exclusions from the patentees’ rights is necessary in order to protect the 
interests of other social groups. The critics of current plant protection 
systems argue that the absoluteness of the patent protection could lead to the 
                                                          
75Sheff, J. N. Self-Replicating Technologies. Stan. Tech. L. Rev. 229(2013).P. 241. 
76Ibid. P. 242. 
77Ibid. P. 243. 
78Ibid. P. 244. 
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monopolies and to the increases of the food prices. This also would not help 
in solving food shortage problems in some regions of the world; on the 
contrary it could lead to even greater isolation between different social 
groups. According to Meienberg, the “states should only introduce 
monopolies if the anticipated benefit – innovation – is greater than the 
damage caused”79. That means that the lawmakers should take into account 
not only the interests of the business, but also the views and needs of other 
stakeholders. The list of important objectives to which special attention 
should be made, according to Meienberg, contains “compliance with human 
rights (in particular the right to food), promotion of the domestic economy, 
promotion of national research, protection and promotion of biodiversity”, 
etc. Professor De Schutter has similar opinion; he argues that “the 
oligopolistic structure of the input providers’ market may result in poor 
farmers being deprived of access to seeds productive resources essential for 
their livelihoods, and it could raise the price of food, thus making food less 
affordable for the poorest”80. This example perfectly illustrates how 
improperly regulated plant protection systems can infringe the right to food. 
Another issue that is important in this context,especially when analysing the 
Bowman v. Monsanto from the European perspective, is legislator’s failure 
to take into account national characteristics of agricultural field and the 
needs of particular country. In the context of Professor’s De Schutter 
assertion that “states should prepare right-to-food impact assessments in 
order to ensure that the IPRs which will be chosen will correspond to their 
development needs”81, it should be noted that current regulation of plants 
patent protection in the European Union cannot be considered as 
corresponding the needs of individual EU member states. This conclusion is 
based on the fact that the exhaustive list indicating the types of plant 
varieties the growing of which may justify the application of the farmer’s 
privilege was made without taking into account the information that the 
farmers of different member states of the EU grow different crops (for 
example, grapesare widely grown insouthernEurope, but this is not the case 
in the northern part of Europe.).  
 
  
                                                          
79Meienberg, F. Infringement of farmers’ rights. D+C, 2010/04, Focus. P. 156. 
80 De Schutter, O. “The right to food – Seed policies and the right to food: enhancing 
agrobiodiversity and encouraging innovation”. Report to the UN General Assembly. 
(October 2009). P.10. Retrieved 05.04.2014 
from<http://www.srfood.org/images/stories/pdf/officialreports/20091021_report-ga64_seed-
policies-and-the-right-to-food_en.pdf>. 
81Ibid. P. 7. 
European Scientific Journal December  2014 edition vol.10, No.34 ISSN: 1857 – 7881 (Print)  e - ISSN 1857- 7431 
42 
Conclusion 
With regard to the analysis of abovementioned legislation of the 
United States and the European Union, it can be concluded, that despite 
some differences in the regulation of the patent protection in the field of 
biological matter, even if the Bowman v. Monsanto case had been examined 
in Europe, the final decision of the European court would not differ from the 
judgment of the US Supreme Court. Although the European patent laws 
(unlike the US Patent Act) contain provisions establishing farmer’s privilege, 
Mr Bowman still would lose the case before the European court because the 
application of this farmer’s privilege is a subject to certain conditions. The 
European court would decide in favour of the patent owner, because Mr 
Bowman cannot be considered as small farmer and because the crops that are 
a matter of the dispute in the Bowman v. Monsanto case (i.e. soya beans) are 
not included into the list provided in the EU legislation. 
Since one of the strategic activities of the European Union is a 
Common Agricultural Policy which has always been and still is a very 
important element of the European integration, the European legislator 
established specific exclusion to the patent protection in the field of 
biotechnological inventions. However, since the European Union also 
stimulates the development of scientific research and innovations that 
promotes economic growth and competitiveness in Europe, the application of 
the abovementioned exclusion is a subject to several conditions. Such 
regulation aims to harmonize the different interests of the representatives of 
technology and agricultural fields. Nevertheless, the author of this 
articlebelieves thatsuch European regulation of the patent protection on 
biological matter does not sufficiently takeinto account the interests of 
allstakeholders and farming particularities in the individual EU member 
states and therefore this regulation should be improved. 
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